新药审批诺诚健华 BCL2抑制剂7月14日,诺诚健华宣布,其自主研发的新型BCL2抑制剂mesutoclax(ICP-248)联合阿扎胞苷治疗髓系恶性肿瘤,包括急性髓系白血病(AML)和骨髓增生异常综合征(MDS),已获得FDA批准开展临床研究。悦康药业 YKYY029注射液7月16日,悦康医药宣布,其1类新药YKYY029注射液获批临床,拟开发治疗高血压。华东医药 HDM20127月17日,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.